Stock comparison
Genmab A/S
Rigel Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
RIGL
Rigel Pharmaceuticals
Market cap
$536.75M
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | RIGL | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 47D | GMAB |
| Benjamin Graham | 64C | 34F | GMAB |
| Philip Fisher | 48D | 54C | RIGL |
| Peter Lynch | 25F | 54C | RIGL |
| Joel Greenblatt | 76B | 48D | GMAB |
| Charlie Munger | 68C | 62D | GMAB |
| Terry Smith | 71C | 61C | GMAB |
Side-by-side metrics
| Metric | GMAB | RIGL |
|---|---|---|
| Market cap | $16.5B | $536.75M |
| P/E (TTM) | 6.2x | 1.4x |
| EV/EBIT | 12.0x | 4.3x |
| ROIC (TTM) | 43.78% | 27.96% |
| Gross margin | 93.88% | 93.39% |
| Net margin | 18.23% | 121.51% |
| Revenue CAGR 5y | -18.45% | 18.5% |
| EPS CAGR 5y | -23.48% | - |
| Debt / Equity | 0.1x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Market cap$16.5Bvs $536.75M+97%
- ROIC (TTM)43.78%vs 27.96%+36%
- Debt / Equity0.1xvs 0.1x+36%
RIGL leads on
- Revenue CAGR 5y18.5%vs -18.45%+200%
- Net margin121.51%vs 18.23%+85%
- P/E (TTM)1.4xvs 6.2x+77%
- EV/EBIT4.3xvs 12.0x+64%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.